Cargando…

Pharmacological Potential of Hippophae rhamnoides L. Nano-Emulsion for Management of Polycystic Ovarian Syndrome in Animals’ Model: In Vitro and In Vivo Studies

[Image: see text] The most common female endocrinopathy, polycystic ovarian syndrome (PCOS), generally affects women of childbearing age. Hippophae rhamnoides L. has been traditionally used to improve menstrual cyclicity. Gas chromatography by flame ionization detection analysis showed that it conta...

Descripción completa

Detalles Bibliográficos
Autores principales: Hussain, Liaqat, Rana, Saba, Abbas, Ghulam, Alshammari, Abdulrahman, Alasmari, Abdullah F., Alharbi, Metab, Zahid, Muhammad Toseef, Irfan, Muhammad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2023
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10500670/
https://www.ncbi.nlm.nih.gov/pubmed/37720770
http://dx.doi.org/10.1021/acsomega.3c04720
_version_ 1785105958040502272
author Hussain, Liaqat
Rana, Saba
Abbas, Ghulam
Alshammari, Abdulrahman
Alasmari, Abdullah F.
Alharbi, Metab
Zahid, Muhammad Toseef
Irfan, Muhammad
author_facet Hussain, Liaqat
Rana, Saba
Abbas, Ghulam
Alshammari, Abdulrahman
Alasmari, Abdullah F.
Alharbi, Metab
Zahid, Muhammad Toseef
Irfan, Muhammad
author_sort Hussain, Liaqat
collection PubMed
description [Image: see text] The most common female endocrinopathy, polycystic ovarian syndrome (PCOS), generally affects women of childbearing age. Hippophae rhamnoides L. has been traditionally used to improve menstrual cyclicity. Gas chromatography by flame ionization detection analysis showed that it contained various phytoconstituents such as omega-3 fatty acid, phytosterols, palmitic acid, oleic acid, and linoleic acid. H. rhamnoides L. (HR) nano-emulsion was also formulated. HR and its encapsulated nano-emulsion (HRNE) were evaluated for the treatment of PCOS. Thirty-five healthy female adult albino rats were acquired and divided into seven groups (n = 5). Letrozole (1 mg/kg) was used for 5 weeks to induce the disease. To confirm disease (PCOS) induction, the animals were weighed weekly and their vaginal smears were analyzed daily under a microscope. After PCOS induction, animals were treated with metformin, HR, and HRNE with two different doses (0.5/kg and 1 g/kg, p.o.) for 5 weeks. At the end of the treatment, animals were euthanized, and blood was collected for hormonal assessment, lipid profiling, and liver functioning test assessment. Both the ovaries were preserved for histopathology and liver for the purpose of assessment of antioxidant potential. The results revealed that HR and HRNE at both doses improved the hormonal imbalance; follicle-stimulating hormone, estrogen, and progesterone levels are increased, while luteinizing hormone surge and testosterone level are controlled. Insulin sensitivity is improved. Ovarian histopathology showed that normal ovarian echotexture is restored with corpus luteum and mature and developing follicles. HR and HRNE also improved the lipid profile and decreased lipid peroxidation (MDA) with improved antioxidant markers (SOD, CAT, and GSH). Results were statistically analyzed by one-way analysis of variance and were considered significant only if p < 0.05. In conclusion, it can be postulated that H. rhamnoides L. proved effective in the management of PCOS and its nano-emulsion effects were statistically more significant, which might be due to better bioavailability.
format Online
Article
Text
id pubmed-10500670
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-105006702023-09-15 Pharmacological Potential of Hippophae rhamnoides L. Nano-Emulsion for Management of Polycystic Ovarian Syndrome in Animals’ Model: In Vitro and In Vivo Studies Hussain, Liaqat Rana, Saba Abbas, Ghulam Alshammari, Abdulrahman Alasmari, Abdullah F. Alharbi, Metab Zahid, Muhammad Toseef Irfan, Muhammad ACS Omega [Image: see text] The most common female endocrinopathy, polycystic ovarian syndrome (PCOS), generally affects women of childbearing age. Hippophae rhamnoides L. has been traditionally used to improve menstrual cyclicity. Gas chromatography by flame ionization detection analysis showed that it contained various phytoconstituents such as omega-3 fatty acid, phytosterols, palmitic acid, oleic acid, and linoleic acid. H. rhamnoides L. (HR) nano-emulsion was also formulated. HR and its encapsulated nano-emulsion (HRNE) were evaluated for the treatment of PCOS. Thirty-five healthy female adult albino rats were acquired and divided into seven groups (n = 5). Letrozole (1 mg/kg) was used for 5 weeks to induce the disease. To confirm disease (PCOS) induction, the animals were weighed weekly and their vaginal smears were analyzed daily under a microscope. After PCOS induction, animals were treated with metformin, HR, and HRNE with two different doses (0.5/kg and 1 g/kg, p.o.) for 5 weeks. At the end of the treatment, animals were euthanized, and blood was collected for hormonal assessment, lipid profiling, and liver functioning test assessment. Both the ovaries were preserved for histopathology and liver for the purpose of assessment of antioxidant potential. The results revealed that HR and HRNE at both doses improved the hormonal imbalance; follicle-stimulating hormone, estrogen, and progesterone levels are increased, while luteinizing hormone surge and testosterone level are controlled. Insulin sensitivity is improved. Ovarian histopathology showed that normal ovarian echotexture is restored with corpus luteum and mature and developing follicles. HR and HRNE also improved the lipid profile and decreased lipid peroxidation (MDA) with improved antioxidant markers (SOD, CAT, and GSH). Results were statistically analyzed by one-way analysis of variance and were considered significant only if p < 0.05. In conclusion, it can be postulated that H. rhamnoides L. proved effective in the management of PCOS and its nano-emulsion effects were statistically more significant, which might be due to better bioavailability. American Chemical Society 2023-08-28 /pmc/articles/PMC10500670/ /pubmed/37720770 http://dx.doi.org/10.1021/acsomega.3c04720 Text en © 2023 The Authors. Published by American Chemical Society https://creativecommons.org/licenses/by-nc-nd/4.0/Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Hussain, Liaqat
Rana, Saba
Abbas, Ghulam
Alshammari, Abdulrahman
Alasmari, Abdullah F.
Alharbi, Metab
Zahid, Muhammad Toseef
Irfan, Muhammad
Pharmacological Potential of Hippophae rhamnoides L. Nano-Emulsion for Management of Polycystic Ovarian Syndrome in Animals’ Model: In Vitro and In Vivo Studies
title Pharmacological Potential of Hippophae rhamnoides L. Nano-Emulsion for Management of Polycystic Ovarian Syndrome in Animals’ Model: In Vitro and In Vivo Studies
title_full Pharmacological Potential of Hippophae rhamnoides L. Nano-Emulsion for Management of Polycystic Ovarian Syndrome in Animals’ Model: In Vitro and In Vivo Studies
title_fullStr Pharmacological Potential of Hippophae rhamnoides L. Nano-Emulsion for Management of Polycystic Ovarian Syndrome in Animals’ Model: In Vitro and In Vivo Studies
title_full_unstemmed Pharmacological Potential of Hippophae rhamnoides L. Nano-Emulsion for Management of Polycystic Ovarian Syndrome in Animals’ Model: In Vitro and In Vivo Studies
title_short Pharmacological Potential of Hippophae rhamnoides L. Nano-Emulsion for Management of Polycystic Ovarian Syndrome in Animals’ Model: In Vitro and In Vivo Studies
title_sort pharmacological potential of hippophae rhamnoides l. nano-emulsion for management of polycystic ovarian syndrome in animals’ model: in vitro and in vivo studies
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10500670/
https://www.ncbi.nlm.nih.gov/pubmed/37720770
http://dx.doi.org/10.1021/acsomega.3c04720
work_keys_str_mv AT hussainliaqat pharmacologicalpotentialofhippophaerhamnoideslnanoemulsionformanagementofpolycysticovariansyndromeinanimalsmodelinvitroandinvivostudies
AT ranasaba pharmacologicalpotentialofhippophaerhamnoideslnanoemulsionformanagementofpolycysticovariansyndromeinanimalsmodelinvitroandinvivostudies
AT abbasghulam pharmacologicalpotentialofhippophaerhamnoideslnanoemulsionformanagementofpolycysticovariansyndromeinanimalsmodelinvitroandinvivostudies
AT alshammariabdulrahman pharmacologicalpotentialofhippophaerhamnoideslnanoemulsionformanagementofpolycysticovariansyndromeinanimalsmodelinvitroandinvivostudies
AT alasmariabdullahf pharmacologicalpotentialofhippophaerhamnoideslnanoemulsionformanagementofpolycysticovariansyndromeinanimalsmodelinvitroandinvivostudies
AT alharbimetab pharmacologicalpotentialofhippophaerhamnoideslnanoemulsionformanagementofpolycysticovariansyndromeinanimalsmodelinvitroandinvivostudies
AT zahidmuhammadtoseef pharmacologicalpotentialofhippophaerhamnoideslnanoemulsionformanagementofpolycysticovariansyndromeinanimalsmodelinvitroandinvivostudies
AT irfanmuhammad pharmacologicalpotentialofhippophaerhamnoideslnanoemulsionformanagementofpolycysticovariansyndromeinanimalsmodelinvitroandinvivostudies